Methotrexate Clinical Research Samples

Discovery Life Sciences provides the highest quality Methotrexate Clinical Research Samples and Residual Diagnostic Specimens from the Life Science Industry’s only convenient online, open access Biobank. 

  • All Methotrexate Sample Orders are Packaged for Delivery within 24 Hours. 
  • All Specimens Ethically Obtained, De-Identified and provided with Highly Annotated Demographic and Clinical Data.
  • Select from an HHS/OHRP Compliant Biorepository following ISBER/BBRB Guidelines.
  • Packaged in Compliance with all UN Regulations (6.2) and U.S. DOT Hazmat regulations. 
Advanced Data View:
Showing 222 of 222 total samples
Buy
Product IDSampleOriginMatrixVial (ml)QuantityPriceAgeGenderEthnicityStorage TempSample DateTest 1Test Data 1Sample Detail 1Test 2Test Data 2Test 3Test Data 3Sample Detail 3Product
Details
Price
Buy
Additional Information 1Additional Data 1Additional Information 2Additional Data 2Additional Detail 2Additional Information 3Additional Data 3Additional Information 4Additional Data 4Additional Information 5Additional Data 5Additional Information 6Additional Data 6Additional Information 7Additional Data 7ICD10 codes
DLS15-14151MethotrexateUSANa Heparin1.501.00$75.0066 YMWhite<-70C02-Oct-15Roche cobas c5020.05 umol/LMethotrexate$75.00C85.80
DLS15-14152MethotrexateUSANa Heparin1.501.00$75.0060 YFWhite<-70C02-Oct-15Roche cobas c5020.11 umol/LMethotrexate$75.00C91.00
DLS15-14184MethotrexateUSANa Heparin1.501.00$75.0062 YMWhite<-70C11-Oct-15Roche cobas c5020.11 umol/LMethotrexate$75.00C85.90
DLS15-14229MethotrexateUSANa Heparin1.501.00$75.0039 YMWhite<-70C15-Oct-15Roche cobas c5020.16 umol/LMethotrexate$75.00C41.9
DLS15-14230MethotrexateUSANa Heparin1.501.00$75.0039 YMWhite<-70C15-Oct-15Roche cobas c5020.13 umol/LMethotrexate$75.00C41.9
DLS15-14232MethotrexateUSANa Heparin1.501.00$75.0039 YMWhite<-70C16-Oct-15Roche cobas c5020.09 umol/LMethotrexate$75.00C41.9
DLS15-14233MethotrexateUSANa Heparin1.501.00$75.0063 YFWhite<-70C16-Oct-15Roche cobas c5020.05 umol/LMethotrexate$75.00C83.30
DLS15-14251MethotrexateUSANa Heparin1.501.00$75.0039 YMWhite<-70C20-Oct-15Roche cobas c5025.50 umol/LMethotrexate$75.00C41.9
DLS15-17953MethotrexateUSAK2 EDTA Plasma1.251.00$75.0062 YMWhite<-70C24-Dec-15Roche cobas c5026.9 umol/LMethotrexate$75.00C85.90 K21.9 D75.89
DLS15-08688MethotrexateUSAL. Heparin Plasma1.001.00$75.0019 YFWhite<-70C18-May-16Roche cobas c50219 umol/LMethotrexate$75.00C78.00 E44.0 D70.9
DLS15-08783MethotrexateUSAL. Heparin Plasma1.251.00$75.0018 YMAsian<-70C31-May-16Roche cobas c5027.2 umol/LMethotrexate$75.00M25.862 C41.9 D70.9
DLS16-31329MethotrexateUSAL. Heparin Plasma1.001.00$75.0014 YFBlack<-70C21-Jun-16Roche cobas c5027.1 umol/LMethotrexate$75.00C40.22 R50.9 C41.9
DLS16-31461MethotrexateUSAL. Heparin Plasma1.501.00$75.0018 YMAsian<-70C09-Jul-16Roche cobas c5027.8 umol/LMethotrexate$75.00C41.9 D70.9 K12.31
DLS16-23867-SMethotrexateRussiaSerum1.006.00$150.0076 YFWhite<-70C07-Jul-16Abbott TDx FLx1.87 ug/mLMethotrexateClinical DiagnosisCervical Cancer (C53)StagingStage IV; T3N1M1G324-Jun-16$150.00Menopausal StatusPostSmoking HistoryFormer10-15 per day for 20 years Date of Initial Primary Tumor Diagnosis19-Jun-16Site of Primary TumorCervixSite of MetastasisBladderHistory of Benign Disease Prior to Cancer Diagnosis No Current MedicationsNone
DLS16-23876-SMethotrexateRussiaSerum1.008.00$150.0061 YMWhite<-70C04-Jul-16Abbott TDx FLx0.67 ug/mLMethotrexateClinical DiagnosisNon-Hodgkin lymphoma, T-Cell LymphomaStagingStage IV; Grade G229-May-16$150.00Menopausal StatusN/ASmoking HistoryFormer10-20 per day for 20 years Date of Initial Primary Tumor Diagnosis28-May-16Site of Primary TumorRegional Nodes, MediastinumSite of MetastasisBone Marrow, LiverHistory of Benign Disease Prior to Cancer Diagnosis No Current MedicationsNone
DLS16-23876-LHMethotrexateRussiaL. Heparin Plasma1.002.00$150.0061 YMWhite<-70C04-Jul-16Abbott TDx FLx0.67 ug/mLMethotrexateClinical DiagnosisNon-Hodgkin lymphoma, T-Cell LymphomaStagingStage IV; Grade G229-May-16$150.00Menopausal StatusN/ASmoking HistoryFormer10-20 per day for 20 years Date of Initial Primary Tumor Diagnosis28-May-16Site of Primary TumorRegional Nodes, MediastinumSite of MetastasisBone Marrow, LiverHistory of Benign Disease Prior to Cancer DiagnosisNoCurrent MedicationsNone
DLS16-23878-SMethotrexateRussiaSerum1.008.00$150.0030 YFWhite<-70C25-Jul-16Abbott TDx FLx2.02 ug/mLMethotrexateClinical DiagnosisGestational Trophoblastic Neoplasia (C58)StagingStage I; T1N0M0G311-Jul-16$150.00Menopausal StatusPreSmoking HistoryNoneN/A Date of Initial Primary Tumor Diagnosis15-Jun-16Site of Primary TumorUterusSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23878-LHMethotrexateRussiaL. Heparin Plasma1.501.00$150.0030 YFWhite<-70C25-Jul-16Abbott TDx FLx2.02 ug/mLMethotrexateClinical DiagnosisGestational Trophoblastic Neoplasia (C58)StagingStage I; T1N0M0G311-Jul-16$150.00Menopausal StatusPreSmoking HistoryNoneN/A Date of Initial Primary Tumor Diagnosis15-Jun-16Site of Primary TumorUterusSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23879-SMethotrexateRussiaSerum1.005.00$150.0062 YFWhite<-70C23-Jun-16Abbott TDx FLx2.53 ug/mLMethotrexateClinical DiagnosisNon-Hodgkin lymphomaStagingStage III; Grade G212-Feb-11$150.00Menopausal StatusPostSmoking HistoryFormer8-10 per day for 30 years Date of Initial Primary Tumor Diagnosis8-Feb-11Site of Primary TumorMediastinum Site of MetastasisRegional NodesHistory of Benign Disease Prior to Cancer DiagnosisNoCurrent MedicationsNone
DLS16-23879-LHMethotrexateRussiaL. Heparin Plasma1.002.00$150.0062 YFWhite<-70C23-Jun-16Abbott TDx FLx2.53 ug/mLMethotrexateClinical DiagnosisNon-Hodgkin lymphomaStagingStage III; Grade G212-Feb-11$150.00Menopausal StatusPostSmoking HistoryFormer8-10 per day for 30 years Date of Initial Primary Tumor Diagnosis8-Feb-11Site of Primary TumorMediastinum Site of MetastasisRegional NodesHistory of Benign Disease Prior to Cancer DiagnosisNo Current MedicationsNone
DLS16-23884-SMethotrexateRussiaSerum1.007.00$150.0054 YMWhite<-70C10-Jun-16Abbott TDx FLx0.40 ug/mLMethotrexateClinical DiagnosisNon-Hodgkin lymphomaStagingStage IV; Grade G214-May-16$150.00Menopausal StatusMenopauseSmoking HistoryFormer15-20 per day for 20 years Date of Initial Primary Tumor Diagnosis11-May-16Site of Primary TumorBone MarrowSite of MetastasisMediastinum, Liver, Central Nervous SystemHistory of Benign Disease Prior to Cancer Diagnosis No Current MedicationsNone
DLS16-23884-LHMethotrexateRussiaL. Heparin Plasma1.002.00$150.0054 YMWhite<-70C10-Jun-16Abbott TDx FLx0.40 ug/mLMethotrexateClinical DiagnosisNon-Hodgkin lymphomaStagingStage IV; Grade G214-May-16$150.00Menopausal StatusMenopauseSmoking HistoryFormer15-20 per day for 20 years Date of Initial Primary Tumor Diagnosis11-May-16Site of Primary TumorBone MarrowSite of MetastasisMediastinum, Liver, Central Nervous SystemHistory of Benign Disease Prior to Cancer Diagnosis No Current MedicationsNone
DLS16-23887-SMethotrexateRussiaSerum1.004.00$150.0065 YFWhite<-70C26-Jul-16Abbott TDx FLx0.10 ug/mLMethotrexateClinical DiagnosisCervical Cancer (C53)StagingStage III; T3N1M0G211-Jul-16$150.00Menopausal StatusPostSmoking HistoryFormer8-10 per day for 30 years Date of Initial Primary Tumor Diagnosis7-Jul-16Site of Primary TumorCervixSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsCisplatin; Bleomycin; Fluorouracil; Ondansetron
DLS16-23887-LHMethotrexateRussiaL. Heparin Plasma1.001.00$150.0065 YFWhite<-70C26-Jul-16Abbott TDx FLx0.10 ug/mLMethotrexateClinical DiagnosisCervical Cancer (C53)StagingStage III; T3N1M0G211-Jul-16$150.00Menopausal StatusPostSmoking HistoryFormer8-10 per day for 30 years Date of Initial Primary Tumor Diagnosis7-Jul-16Site of Primary TumorCervixSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsCisplatin; Bleomycin; Fluorouracil; Ondansetron
DLS16-23888-SMethotrexateRussiaSerum1.007.00$150.0062 YFWhite<-70C05-Jul-16Abbott TDx FLx5.14 ug/mLMethotrexateClinical DiagnosisCervical Cancer (C53)StagingStage III; T3N2M0G326-May-16$150.00Menopausal StatusPostSmoking HistoryFormer5-10 per day for 15-17 years Date of Initial Primary Tumor Diagnosis18-May-16Site of Primary TumorCervixSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsCisplatin; Bleomycin; Fluorouracil; Palonosetron
DLS16-23892-SMethotrexateRussiaSerum1.007.00$150.0069 YFWhite<-70C12-Aug-16Abbott TDx FLx0.08 ug/mLMethotrexateClinical DiagnosisEndometrial Adenocarcinoma (C54)StagingStage III; T3N1M0G315-Jul-16$150.00Menopausal StatusPostSmoking HistoryNoneN/A Date of Initial Primary Tumor Diagnosis18-Jun-16Site of Primary TumorCorpus UteriSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsEndoxan; Fluorouracil; Ondansetron
DLS16-23893-SMethotrexateRussiaSerum1.007.00$150.0064 YFWhite<-70C15-Jul-16Abbott TDx FLx3.16 ug/mLMethotrexateClinical DiagnosisCancer Corpus Uteri (C54)StagingStage III; T3N1M0G314-May-16$150.00Menopausal StatusPostSmoking HistoryFormer10-12 per day for 20 years Date of Initial Primary Tumor Diagnosis28-Apr-15Site of Primary TumorCorpus UteriSite of MetastasisN/AHistory of Benign Disease Prior to Cancer DiagnosisYes Current MedicationsEndoxan; Fluorouracil; Ondansetron
DLS16-23893-LHMethotrexateRussiaL. Heparin Plasma1.001.00$150.0064 YFWhite<-70C15-Jul-16Abbott TDx FLx3.16 ug/mLMethotrexateClinical DiagnosisCancer Corpus Uteri (C54)StagingStage III; T3N1M0G314-May-16$150.00Menopausal StatusPostSmoking HistoryFormer10-12 per day for 20 years Date of Initial Primary Tumor Diagnosis28-Apr-15Site of Primary TumorCorpus UteriSite of MetastasisN/AHistory of Benign Disease Prior to Cancer Diagnosis Yes Current MedicationsEndoxan; Fluorouracil; Ondansetron
DLS16-23894-SMethotrexateRussiaSerum1.008.00$150.0068 YFWhite<-70C17-Jun-16Abbott TDx FLx3.33 ug/mLMethotrexateClinical DiagnosisOvarian Cancer (C56)StagingStage III; T3N1M0G217-May-16$150.00Menopausal StatusPostSmoking HistoryFormer5-10 per day for 30 years Date of Initial Primary Tumor Diagnosis10-May-16Site of Primary TumorOvarySite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsEndoxan; Methotrexate; Fluorouracil
DLS16-23894-LHMethotrexateRussiaL. Heparin Plasma1.002.00$150.0068 YFWhite<-70C17-Jun-16Abbott TDx FLx3.33 ug/mLMethotrexateClinical DiagnosisOvarian Cancer (C56)StagingStage III; T3N1M0G217-May-16$150.00Menopausal StatusPostSmoking HistoryFormer5-10 per day for 30 years Date of Initial Primary Tumor Diagnosis10-May-16Site of Primary TumorOvarySite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsEndoxan; Methotrexate; Fluorouracil
DLS16-23903-SMethotrexateRussiaSerum1.002.00$150.0070 YFWhite<-70C11-Jul-16Abbott TDx FLx2.76 ug/mLMethotrexateClinical DiagnosisCervical Cancer (C53)StagingStage III; T3N2M0G313-Jun-16$150.00Menopausal StatusPostSmoking HistoryFormer5-10 per day for 40 years Date of Initial Primary Tumor Diagnosis29-May-16Site of Primary TumorCervixSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsBleomycin; Fluorouracil
DLS16-23904-SMethotrexateRussiaSerum1.007.00$150.0072 YFWhite<-70C07-Jun-16Abbott TDx FLx2.51 ug/mLMethotrexateClinical DiagnosisNon-Hodgkin lymphoma (DLBCL)StagingStage IV; Grade G229-Nov-12$150.00Menopausal StatusPostSmoking HistoryFormer10-12 per day for 50 years Date of Initial Primary Tumor Diagnosis24-Nov-12Site of Primary TumorRegional (Axillary) NodeSite of MetastasisLiver, Bone MarrowHistory of Benign Disease Prior to Cancer Diagnosis No Current MedicationsNone
DLS16-23904-LHMethotrexateRussiaL. Heparin Plasma1.002.00$150.0072 YFWhite<-70C07-Jun-16Abbott TDx FLx2.51 ug/mLMethotrexateClinical DiagnosisNon-Hodgkin lymphoma (DLBCL)StagingStage IV; Grade G229-Nov-12$150.00Menopausal StatusPostSmoking HistoryFormer10-12 per day for 50 years Date of Initial Primary Tumor Diagnosis24-Nov-12Site of Primary TumorRegional (Axillary) NodeSite of MetastasisLiver, Bone MarrowHistory of Benign Disease Prior to Cancer Diagnosis No Current MedicationsNone
DLS16-23906-SMethotrexateRussiaSerum1.0010.00$150.0041 YFWhite<-70C15-Jun-16Abbott TDx FLx3.53 ug/mLMethotrexateClinical DiagnosisCancer Colli Uteri (C53)StagingStage IV; T3N1M1G216-Apr-16$150.00Menopausal StatusPreSmoking HistoryFormer5-10 per day for 10 years Date of Initial Primary Tumor Diagnosis2-Mar-16Site of Primary TumorCervixSite of MetastasisRegional NodesHistory of Benign Disease Prior to Cancer Diagnosis No Current MedicationsBleomycin; Fluorouracil
DLS16-23906-LHMethotrexateRussiaL. Heparin Plasma1.001.00$150.0041 YFWhite<-70C15-Jun-16Abbott TDx FLx3.53 ug/mLMethotrexateClinical DiagnosisCancer Colli Uteri (C53)StagingStage IV; T3N1M1G216-Apr-16$150.00Menopausal StatusPreSmoking HistoryFormer5-10 per day for 10 years Date of Initial Primary Tumor Diagnosis2-Mar-16Site of Primary TumorCervixSite of MetastasisRegional NodesHistory of Benign Disease Prior to Cancer Diagnosis No Current MedicationsBleomycin; Fluorouracil
DLS16-23907-SMethotrexateRussiaSerum1.005.00$150.0051 YFWhite<-70C23-Jun-16Abbott TDx FLx0.11 ug/mLMethotrexateClinical DiagnosisCancer Colli Uteri (C53)StagingStage III; T2N1M0G214-May-16$150.00Menopausal StatusPostSmoking HistoryNoneN/A Date of Initial Primary Tumor Diagnosis3-Apr-16Site of Primary TumorCervixSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsBleomycin; Fluorouracil
DLS16-23914-SMethotrexateRussiaSerum1.009.00$150.0061 YFWhite<-70C15-Jun-16Abbott TDx FLx0.04 ug/mLMethotrexateClinical DiagnosisCorpus Uteri Cancer (C54)StagingStage III; T3N1M0G219-May-16$150.00Menopausal StatusPostSmoking HistoryFormer10-12 per day for 25 years Date of Initial Primary Tumor Diagnosis28-Apr-16Site of Primary TumorCorpus UteriSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsEndoxan; Fluorouracil
DLS16-23882-SMethotrexateRussiaSerum1.005.00$150.0044 YFAsian<-70C08-Sep-16Abbott TDx FLx2.58 ug/mLMethotrexateClinical DiagnosisOvarian Cancer (C56)StagingStage III; T3N2M0G317-Aug-16$150.00Menopausal StatusN/ASmoking HistoryNoneN/A Date of Initial Primary Tumor Diagnosis25-Jul-16Site of Primary TumorOvary (right)Site of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23882-LHMethotrexateRussiaL. Heparin Plasma1.251.00$150.0044 YFAsian<-70C08-Sep-16Abbott TDx FLx2.58 ug/mLMethotrexateClinical DiagnosisOvarian Cancer (C56)StagingStage III; T3N2M0G317-Aug-16$150.00Menopausal StatusN/ASmoking HistoryNoneN/A Date of Initial Primary Tumor Diagnosis25-Jul-16Site of Primary TumorOvary (right)Site of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23883-SMethotrexateRussiaSerum1.003.00$150.0056 YFWhite<-70C14-Sep-16Abbott TDx FLx2.03 ug/mLMethotrexateClinical DiagnosisCervical Cancer (C53)StagingStage II; T2N0M0G330-Aug-16$150.00Menopausal StatusMenopauseSmoking HistoryFormer5-10 per day for 25 years Date of Initial Primary Tumor Diagnosis29-Jul-16Site of Primary TumorCervixSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23886-SMethotrexateRussiaSerum1.0010.00$150.0058 YFAsian<-70C06-Oct-16Abbott TDx FLx1.16 ug/mLMethotrexateClinical DiagnosisEndometrial Cancer (C54)StagingStage III; T3NXM0G24-Sep-16$150.00Menopausal StatusPostSmoking HistoryFormer5-8 per day for 5 years Date of Initial Primary Tumor Diagnosis18-Aug-16Site of Primary TumorCorpus UteriSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23886-LHMethotrexateRussiaL. Heparin Plasma1.001.00$150.0058 YFAsian<-70C06-Oct-16Abbott TDx FLx1.16 ug/mLMethotrexateClinical DiagnosisEndometrial Cancer (C54)StagingStage III; T3NXM0G24-Sep-16$150.00Menopausal StatusPostSmoking HistoryFormer5-8 per day for 5 years Date of Initial Primary Tumor Diagnosis18-Aug-16Site of Primary TumorCorpus UteriSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23895-SMethotrexateRussiaSerum1.006.00$150.0039 YFWhite<-70C12-Sep-16Abbott TDx FLx2.43 ug/mLMethotrexateClinical DiagnosisOvarian Cancer (C56)StagingStage II; T2NXM0G319-Aug-16$150.00Menopausal StatusN/ASmoking HistoryCurrent8-10 per day for 10 years Date of Initial Primary Tumor Diagnosis20-Jul-16Site of Primary TumorOvary (left)Site of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23908-SMethotrexateRussiaSerum1.0011.00$150.0049 YFAsian<-70C05-Sep-16Abbott TDx FLx1.42 ug/mLMethotrexateClinical DiagnosisCancer Colli Uteri (C53)StagingStage III; T3N1M0G38-Aug-16$150.00Menopausal StatusN/ASmoking HistoryCurrent5-8 per day for 20 years Date of Initial Primary Tumor Diagnosis2-Jul-16Site of Primary TumorCervixSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23908-LHMethotrexateRussiaL. Heparin Plasma1.001.00$150.0049 YFAsian<-70C05-Sep-16Abbott TDx FLx1.42 ug/mLMethotrexateClinical DiagnosisCancer Colli Uteri (C53)StagingStage III; T3N1M0G38-Aug-16$150.00Menopausal StatusN/ASmoking HistoryCurrent5-8 per day for 20 years Date of Initial Primary Tumor Diagnosis2-Jul-16Site of Primary TumorCervixSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23910-SMethotrexateRussiaSerum1.002.00$150.0064 YMWhite<-70C13-Sep-16Abbott TDx FLx0.52 ug/mLMethotrexateClinical DiagnosisNSCLCStagingStage III; T3NXM0G330-Aug-16$150.00Menopausal StatusN/ASmoking HistoryFormer10-20 per day for 30 years Date of Initial Primary Tumor Diagnosis4-Aug-16Site of Primary TumorLung (right)Site of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23911-SMethotrexateRussiaSerum1.004.00$150.0067 YFWhite<-70C16-Sep-16Abbott TDx FLx0.52 ug/mLMethotrexateClinical DiagnosisCancer Corpus Uteri (C54)StagingStage III; T3N1M0G31-Sep-16$150.00Menopausal StatusPostSmoking HistoryCurrent8-10 per day for 40 years Date of Initial Primary Tumor Diagnosis11-Jul-16Site of Primary TumorCorpus UteriSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23911-LHMethotrexateRussiaL. Heparin Plasma1.001.00$150.0067 YFWhite<-70C16-Sep-16Abbott TDx FLx0.52 ug/mLMethotrexateClinical DiagnosisCancer Corpus Uteri (C54)StagingStage III; T3N1M0G31-Sep-16$150.00Menopausal StatusPostSmoking HistoryCurrent8-10 per day for 40 years Date of Initial Primary Tumor Diagnosis11-Jul-16Site of Primary TumorCorpus UteriSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS14-32074MethotrexateUSAL. Heparin Plasma1.251.00$75.0051 YFWhite<-70C15-Jun-16Roche cobas c5021.15 umol/LMethotrexate$75.00C85.81 R00.1 H26.9
DLS14-32078MethotrexateUSAK2 EDTA Plasma1.251.00$75.0057 YFWhite<-70C11-Jun-16Roche cobas c5021.05 umol/LMethotrexate$75.00A41.52 D49.6 N60.19
DLS16-30887MethotrexateUSAL. Heparin Plasma1.251.00$75.0060 YFWhite<-70C23-Jun-16Roche cobas c5022.8 umol/LMethotrexate$75.00G93.6 K91.1 F32.9
DLS16-31455MethotrexateUSAL. Heparin Plasma1.501.00$75.0051 YFWhite<-70C13-Jul-16Roche cobas c5021.03 umol/LMethotrexate$75.00C85.81 R00.1 H26.9
DLS16-32205MethotrexateUSAL. Heparin Plasma1.001.00$75.0013 YMWhite<-70C10-Sep-16Roche cobas c5021.01 umol/LMethotrexate$75.00F80.89 C91.00 L02.91
DLS15-08788MethotrexateUSAL. Heparin Plasma1.001.00$75.0014 YFBlack<-70C26-May-16Roche cobas c5020.21 umol/LMethotrexate$75.00C40.00 R50.9 C41.9
DLS17-017005MethotrexateUSAL. Heparin Plasma1.251.00$75.0052 YFWhite<-70C14-May-17Roche cobas c5020.14 umol/LMethotrexate$75.00D64.81 R11.2 C83.38 C83.30 K59.03 K21.9 E78.5 E03.9 E03.8 M54.5 I80.9
DLS16-23855-LHMethotrexateRussiaL. Heparin Plasma1.001.00$150.0039 YMWhite<-70C30-Sep-16Abbott TDx FLx0.36 ug/mLMethotrexateClinical DiagnosisNHL, T-Cell LymphomaStagingStage IV; Grade G223-May-16$150.00Menopausal StatusN/ASmoking HistoryFormer 10-20 cigs/day 8-10 years Date of Initial Primary Tumor Diagnosis19-May-16Site of Primary TumorRegional (Axillary) NodesSite of MetastasisCentral Nervous System, Bone MarrowWas Subject on previously on ChemotherapyYes 24-May-2016 to 29-May-2016 and 11-Jul-2016 to 16-Jul-2016 Hyper CVADCurrent ChemotherapyRMA (Rituximab,HD-MTX, Ara-C)
DLS16-23855-SMethotrexateRussiaSerum1.0010.00$150.0039 YMWhite<-70C30-Sep-16Abbott TDx FLx0.36 ug/mLMethotrexateClinical DiagnosisNHL, T-Cell LymphomaStagingStage IV; Grade G223-May-16$150.00Menopausal StatusN/ASmoking HistoryFormer 10-20 cigs/day 8-10 years Date of Initial Primary Tumor Diagnosis19-May-16Site of Primary TumorRegional (Axillary) NodesSite of MetastasisCentral Nervous System, Bone MarrowWas Subject on previously on ChemotherapyYes 24-May-2016 to 29-May-2016 and 11-Jul-2016 to 16-Jul-2016 Hyper CVADCurrent ChemotherapyRMA (Rituximab,HD-MTX, Ara-C)
DLS16-23860-LHMethotrexateRussiaL. Heparin Plasma1.001.00$150.0056 YMAsian<-70C26-Oct-16Abbott TDx FLx0.30 ug/mLMethotrexateClinical DiagnosisNHL, B-Cell LymphomaStagingStage III; Grade G316-Jan-15$150.00Menopausal StatusN/ASmoking HistoryFormer 15-20 cigs/day, 10 years Date of Initial Primary Tumor Diagnosis12-Jan-15Site of Primary TumorRegional (Axillary) NodesSite of MetastasisLiver, Mediastinal NodesWas Subject on previously on ChemotherapyYes Jan-2015 - Jul-2015 6 cycles R-CHOPCurrent ChemotherapyHMA (HD-MTX, Ara-C)
DLS16-23860-SMethotrexateRussiaSerum1.008.00$150.0056 YMAsian<-70C26-Oct-16Abbott TDx FLx0.30 ug/mLMethotrexateClinical DiagnosisNHL, B-Cell LymphomaStagingStage III Grade G316-Jan-15$150.00Menopausal StatusN/ASmoking HistoryFormer 15-20 cigs/day 10 years Date of Initial Primary Tumor Diagnosis12-Jan-15Site of Primary TumorRegional (Axillary) NodesSite of MetastasisLiver, Mediastinal NodesWas Subject on previously on ChemotherapyYes Jan-2015 - Jul-2015 6 cycles R-CHOPCurrent ChemotherapyHMA (HD-MTX, Ara-C)
DLS16-23875-LHMethotrexateRussiaL. Heparin Plasma1.001.00$150.0051 YMWhite<-70C03-Aug-16Abbott TDx FLx0.20 ug/mLMethotrexateClinical DiagnosisT-cell Acute Lymphoblastic Leukemia (T-ALL)StagingStage IV1-Jun-16$150.00Menopausal StatusN/ASmoking HistoryFormer 12-15 cigs/day 25 years Date of Initial Primary Tumor Diagnosis31-May-16Site of Primary TumorBone MarrowSite of MetastasisN/AWas Subject on previously on ChemotherapyInduction block (ALL 2009 and since 3-Jun-2016), Current ChemotherapyHD-MTX
DLS16-23875-SMethotrexateRussiaSerum1.008.00$150.0051 YMWhite<-70C03-Aug-16Abbott TDx FLx0.20 ug/mLMethotrexateClinical DiagnosisT-cell Acute Lymphoblastic Leukemia (T-ALL)StagingStage IV1-Jun-16$150.00Menopausal StatusN/ASmoking HistoryFormer 12-15 cigs/day 25 years Date of Initial Primary Tumor Diagnosis31-May-16Site of Primary TumorBone MarrowSite of MetastasisN/AWas Subject on previously on ChemotherapyInduction block (ALL 2009 and since 3-Jun-2016), Current ChemotherapyHD-MTX
DLS16-23877-LHMethotrexateRussiaL. Heparin Plasma1.002.00$150.0056 YMWhite<-70C26-Aug-16Abbott TDx FLx0.13 ug/mLMethotrexateClinical DiagnosisNHL, T-Cell LymphomaStagingStage IV; Grade G324-Jun-16$150.00Menopausal StatusN/ASmoking HistoryFormer 8-15 cigs/day 10 years Date of Initial Primary Tumor Diagnosis20-Jun-16Site of Primary TumorRegional NodesSite of MetastasisLiver, Central Nervous System, Paraaortal NodesWas Subject on previously on ChemotherapyYes 24-Jun-2016 to 29-Jun-2016 Hyper CVADCurrent ChemotherapyHMA (HD-MTX, Ara-C)
DLS16-23877-SMethotrexateRussiaSerum1.005.00$150.0056 YMWhite<-70C26-Aug-16Abbott TDx FLx0.13 ug/mLMethotrexateClinical DiagnosisNHL, T-Cell LymphomaStagingStage IV; Grade G324-Jun-16$150.00Menopausal StatusN/ASmoking HistoryFormer 8-15 cigs/day 10 years Date of Initial Primary Tumor Diagnosis20-Jun-16Site of Primary TumorRegional NodesSite of MetastasisLiver, Central Nervous System, Paraaortal NodesWas Subject on previously on ChemotherapyYes 24-Jun-2016 to 29-Jun-2016 Hyper CVADCurrent ChemotherapyHMA (HD-MTX, Ara-C)
DLS16-23880-LHMethotrexateRussiaL. Heparin Plasma1.002.00$150.0062 YFAsian<-70C04-Oct-16Abbott TDx FLx0.10 ug/mLMethotrexateClinical DiagnosisNHL, T-Cell LymphomaStagingStage IV; Grade G2 17-Jul-16$150.00Menopausal StatusPostSmoking HistoryNoneN/A Date of Initial Primary Tumor Diagnosis12-Jul-16Site of Primary TumorRegional NodesSite of MetastasisLiver, Central Nervous System Was Subject on previously on ChemotherapyYes 17-Jul-2016 to 22-Jul-2016 Hyper CVADCurrent ChemotherapyRMA (Rituximab,HD-MTX, Ara-C)
DLS16-23880-SMethotrexateRussiaSerum1.005.00$150.0062 YFAsian<-70C04-Oct-16Abbott TDx FLx0.10 ug/mLMethotrexateClinical DiagnosisNHL, T-Cell LymphomaStagingStage IV; Grade G2 17-Jul-16$150.00Menopausal StatusPostSmoking HistoryNoneN/A Date of Initial Primary Tumor Diagnosis12-Jul-16Site of Primary TumorRegional NodesSite of MetastasisLiver, Central Nervous System Was Subject on previously on ChemotherapyYes 17-Jul-2016 to 22-Jul-2016 Hyper CVADCurrent ChemotherapyRMA (Rituximab,HD-MTX, Ara-C)
DLS16-23890-LHMethotrexateRussiaL. Heparin Plasma1.001.00$150.0043 YMWhite<-70C28-Jul-16Abbott TDx FLx0.91 ug/mLMethotrexateClinical DiagnosisNHL, B-Cell LymphomaStagingStage IV; Grade G314-Jun-16$150.00Menopausal StatusN/ASmoking HistoryCurrent 10-15 cigs/day 20 years Date of Initial Primary Tumor Diagnosis10-Jun-16Site of Primary TumorCentral Nervous System Site of MetastasisLiver, Mediastinal Nodes, Bone MarrowWas Subject on previously on ChemotherapyInduction block (since 14-Jun-2016), Current ChemotherapyRMA (Rituximab,HD-MTX, Ara-C)
DLS16-23890-SMethotrexateRussiaSerum1.009.00$150.0043 YMWhite<-70C28-Jul-16Abbott TDx FLx0.91 ug/mLMethotrexateClinical DiagnosisNHL, B-Cell LymphomaStagingStage IV; Grade G314-Jun-16$150.00Menopausal StatusN/ASmoking HistoryCurrent10-15 cigs/day 20 years Date of Initial Primary Tumor Diagnosis10-Jun-16Site of Primary TumorCentral Nervous System Site of MetastasisLiver, Mediastinal Nodes, Bone MarrowWas Subject on previously on ChemotherapyInduction block (since 14-Jun-2016), Current ChemotherapyRMA (Rituximab,HD-MTX, Ara-C)
DLS16-23897-LHMethotrexateRussiaL. Heparin Plasma1.001.00$150.0060 YMWhite<-70C08-Sep-16Abbott TDx FLx0.54 ug/mLMethotrexateClinical DiagnosisNHL, T-Cell LymphomaStagingStage IV; Grade G38-Jun-16$150.00Menopausal StatusN/ASmoking HistoryFormer 15-20 cigs/day 35 years Date of Initial Primary Tumor Diagnosis4-Jun-16Site of Primary TumorRegional Nodes (Submandibular, Supraclavicular)Site of MetastasisBone Marrow, LiverWas Subject on previously on ChemotherapyYes since 9-Jun-2016 Hyper CVADCurrent ChemotherapyHD-MTX
DLS16-23897-SMethotrexateRussiaSerum1.008.00$150.0060 YMWhite<-70C08-Sep-16Abbott TDx FLx0.54 ug/mLMethotrexateClinical DiagnosisNHL, T-Cell LymphomaStagingStage IV; Grade G38-Jun-16$150.00Menopausal StatusN/ASmoking HistoryFormer 15-20 cigs/day 35 years Date of Initial Primary Tumor Diagnosis4-Jun-16Site of Primary TumorRegional Nodes (Submandibular, Supraclavicular)Site of MetastasisBone Marrow, LiverWas Subject on previously on ChemotherapyYes since 9-Jun-2016 Hyper CVADCurrent ChemotherapyHD-MTX
DLS16-23899-SMethotrexateRussiaSerum1.004.00$150.0044 YMWhite<-70C28-Sep-16Abbott TDx FLx1.10 ug/mLMethotrexateClinical DiagnosisNHL, B-Cell LymphomaStagingStage IV; Grade G215-Jul-16$150.00Menopausal StatusN/ASmoking HistoryFormer5-15 cigs/day 15 years Date of Initial Primary Tumor Diagnosis10-Jul-16Site of Primary TumorRegional NodesSite of MetastasisLiver, Mediastinal Nodes, Bone MarrowWas Subject on previously on ChemotherapyYes 15-Jul-2016 to 20-Jul-2016 1 cycle R-CHOP 8-Aug-2016 to 14-Aug-2016 Hyper CVADCurrent ChemotherapyHD-MTX
DLS16-23909-LHMethotrexateRussiaL. Heparin Plasma1.001.00$150.0058 YMWhite<-70C07-Oct-16Abbott TDx FLx0.77 ug/mLMethotrexateClinical DiagnosisAcute Lymphoblastic Leukemia (ALL)StagingStage IV14-Aug-16$150.00Menopausal StatusN/ASmoking HistoryCurrent 10-15 cigs/day 25 years Date of Initial Primary Tumor Diagnosis12-Aug-16Site of Primary TumorBone MarrowSite of MetastasisTesticular, LiverWas Subject on previously on ChemotherapyYes 15-Aug-2016 to 20-Aug-2016 Hyper CVADCurrent ChemotherapyHD-MTX
DLS16-23909-SMethotrexateRussiaSerum1.009.00$150.0058 YMWhite<-70C07-Oct-16Abbott TDx FLx0.77 ug/mLMethotrexateClinical DiagnosisAcute Lymphoblastic Leukemia (ALL)StagingStage IV14-Aug-16$150.00Menopausal StatusN/ASmoking HistoryCurrent 10-15 cigs/day 25 years Date of Initial Primary Tumor Diagnosis12-Aug-16Site of Primary TumorBone MarrowSite of MetastasisTesticular, LiverWas Subject on previously on ChemotherapyYes 15-Aug-2016 to 20-Aug-2016 Hyper CVADCurrent ChemotherapyHD-MTX
DLS16-23913-SMethotrexateRussiaSerum1.006.00$150.0058 YMWhite<-70C19-Aug-16Abbott TDx FLx0.56 ug/mLMethotrexateClinical DiagnosisNHL, B-Cell LymphomaStagingStage IV; Grade G28-Jun-16$150.00Menopausal StatusN/ASmoking HistoryFormer 10-20 cigs/day 30 years Date of Initial Primary Tumor Diagnosis6-Jun-16Site of Primary TumorRegional Nodes (Axillary, Subclavicular)Site of MetastasisN/AWas Subject on previously on ChemotherapyYes since 15-Jun-2016 2 cycles R-CHOP Current ChemotherapyHMA (HD-MTX, Ara-C)
DLS16-23862-SMethotrexateRussiaSerum1.006.00$150.0049 YMWhite<-70C21-Nov-16Abbott TDx FLx0.45 uU/mLMethotrexateClinical DiagnosisNHL, T-Cell LymphomaStagingStage IV; Grade G26-Oct-16$150.00Menopausal StatusN/ASmoking HistoryFormer13-15 cigs/day for 15 yearsDate of Initial Primary Tumor Diagnosis3-Oct-2016Site of Primary TumorMediastinal NodesSite of MetastasisBone Marrow Was Subject on previously on ChemotherapyYes, 7-Oct-2016 to 13-Oct Hyper CVADCurrent ChemotherapyHD-MTX
DLS16-23865-LHMethotrexateRussiaL. Heparin Plasma1.002.00$150.0052 YMWhite<-70C22-Dec-16Abbott TDx FLx0.11 uU/mLMethotrexateClinical DiagnosisAnaplastic NHLStagingStage IV; Grade G22-Nov-16$150.00Menopausal StatusN/ASmoking HistoryFormer10-20 cigs/day for 15 yearsDate of Initial Primary Tumor Diagnosis26-Oct-2016Site of Primary TumorRegional (Axillary) NodesSite of MetastasisBone Marrow, LiverWas Subject on previously on ChemotherapyYes since 3-Nov-2016 1 cycle R-CHOPCurrent ChemotherapyRMA (Rituximab,HD-MTX, Ara-C)
DLS16-23865-SMethotrexateRussiaSerum1.006.00$150.0052 YMWhite<-70C22-Dec-16Abbott TDx FLx0.11 uU/mLMethotrexateClinical DiagnosisAnaplastic NHLStagingStage IV; Grade G22-Nov-16$150.00Menopausal StatusN/ASmoking HistoryFormer10-20 cigs/day for 15 yearsDate of Initial Primary Tumor Diagnosis26-Oct-2016Site of Primary TumorRegional (Axillary) NodesSite of MetastasisBone Marrow, LiverWas Subject on previously on ChemotherapyYes since 3-Nov-2016 1 cycle R-CHOPCurrent ChemotherapyRMA (Rituximab,HD-MTX, Ara-C)
DLS16-23866-LHMethotrexateRussiaL. Heparin Plasma1.002.00$150.0050 YMWhite<-70C18-Nov-16Abbott TDx FLx0.10 uU/mLMethotrexateClinical DiagnosisNHL, T-Cell LymphomaStagingStage IV; Grade G315-Jul-16$150.00Menopausal StatusN/ASmoking HistoryFormer5-10 cigs/day for 10 yearsDate of Initial Primary Tumor Diagnosis12-Jul-2016Site of Primary TumorCentral Nervous System (isolated)Site of MetastasisN/AWas Subject on previously on ChemotherapyRituximab and Ara-C since 15-Jul-2016Current ChemotherapyRMA (Rituximab,HD-MTX, Ara-C)
DLS16-23866-SMethotrexateRussiaSerum1.006.00$150.0050 YMWhite<-70C18-Nov-16Abbott TDx FLx0.10 uU/mLMethotrexateClinical DiagnosisNHL, T-Cell LymphomaStagingStage IV; Grade G315-Jul-16$150.00Menopausal StatusN/ASmoking HistoryFormer5-10 cigs/day for 10 yearsDate of Initial Primary Tumor Diagnosis12-Jul-2016Site of Primary TumorCentral Nervous System (isolated)Site of MetastasisN/AWas Subject on previously on ChemotherapyRituximab and Ara-C since 15-Jul-2016Current ChemotherapyRMA (Rituximab,HD-MTX, Ara-C)
DLS16-23871-LHMethotrexateRussiaL. Heparin Plasma1.002.00$150.0049 YMAsian<-70C22-Dec-16Abbott TDx FLx0.38 uU/mLMethotrexateClinical DiagnosisAcute Lymphoblastic Leukemia (ALL) B-cellStagingStage IV17-Oct-16$150.00Menopausal StatusN/ASmoking HistoryFormer15-20 cigs/day for 17-20 yearsDate of Initial Primary Tumor Diagnosis14-Oct-2016Site of Primary TumorBone MarrowSite of MetastasisN/AWas Subject on previously on ChemotherapyInduction block A (ALL 2009 and since 17-Oct-2016), Current ChemotherapyHD-MTX
DLS16-23871-SMethotrexateRussiaSerum1.0010.00$150.0049 YMAsian<-70C22-Dec-16Abbott TDx FLx0.38 uU/mLMethotrexateClinical DiagnosisAcute Lymphoblastic Leukemia (ALL) B-cellStagingStage IV17-Oct-16$150.00Menopausal StatusN/ASmoking HistoryFormer15-20 cigs/day for 17-20 yearsDate of Initial Primary Tumor Diagnosis14-Oct-2016Site of Primary TumorBone MarrowSite of MetastasisN/AWas Subject on previously on ChemotherapyInduction block A (ALL 2009 and since 17-Oct-2016), Current ChemotherapyHD-MTX
DLS16-23881-LHMethotrexateRussiaL. Heparin Plasma1.002.00$150.0064 YFWhite<-70C16-Sep-16Abbott TDx FLx0.67 uU/mLMethotrexateClinical DiagnosisNHL, T-Cell LymphomaStagingStage IV; Grade G323-Jun-16$150.00Menopausal StatusPostSmoking HistoryNoneN/ADate of Initial Primary Tumor Diagnosis23-Jun-2016Site of Primary TumorRegional Nodes (Inguinal ovary)Site of MetastasisRetroperitoneal Nodes, Spleen, Paraaortal NodesWas Subject on previously on ChemotherapyYes since 27-Jun-2016 2 cycles R-EPOCH Current ChemotherapyHD-MTX
DLS16-23881-SMethotrexateRussiaSerum1.004.00$150.0064 YFWhite<-70C16-Sep-16Abbott TDx FLx0.67 uU/mLMethotrexateClinical DiagnosisNHL, T-Cell LymphomaStagingStage IV; Grade G323-Jun-16$150.00Menopausal StatusPostSmoking HistoryNoneN/ADate of Initial Primary Tumor Diagnosis23-Jun-2016Site of Primary TumorRegional Nodes (Inguinal ovary)Site of MetastasisRetroperitoneal Nodes, Spleen, Paraaortal NodesWas Subject on previously on ChemotherapyYes since 27-Jun-2016 2 cycles R-EPOCH Current ChemotherapyHD-MTX
DLS16-23885-LHMethotrexateRussiaL. Heparin Plasma1.001.00$150.0055 YMWhite<-70C21-Nov-16Abbott TDx FLx0.79 uU/mLMethotrexateClinical DiagnosisNHL, B-Cell Lymphoma (relapse)StagingStage III; Grade G218-May-15$150.00Menopausal StatusN/ASmoking HistoryFormer10-12 cigs/day for 20 yearsDate of Initial Primary Tumor Diagnosis3-May-2015Site of Primary TumorRegional Nodes, Spleen (Supraclavicular)Site of MetastasisN/AWas Subject on previously on ChemotherapyYes since 18-May-2015 6 cycles R-CHOPCurrent ChemotherapyHMA (HD-MTX, Ara-C)
DLS16-23885-SMethotrexateRussiaSerum1.006.00$150.0055 YMWhite<-70C21-Nov-16Abbott TDx FLx0.79 uU/mLMethotrexateClinical DiagnosisNHL, B-Cell Lymphoma (relapse)StagingStage III; Grade G218-May-15$150.00Menopausal StatusN/ASmoking HistoryFormer10-12 cigs/day for 20 yearsDate of Initial Primary Tumor Diagnosis3-May-2015Site of Primary TumorRegional Nodes, Spleen (Supraclavicular)Site of MetastasisN/AWas Subject on previously on ChemotherapyYes since 18-May-2015 6 cycles R-CHOPCurrent ChemotherapyHMA (HD-MTX, Ara-C)
DLS16-23889-LHMethotrexateRussiaL. Heparin Plasma1.001.00$150.0064 YFWhite<-70C22-Jul-16Abbott TDx FLx0.81 uU/mLMethotrexateClinical DiagnosisNHL, T-Cell LymphomaStagingStage IV; Grade G324-May-16$150.00Menopausal StatusPostSmoking HistoryFormer10-15 cigs/day for 15 yearsDate of Initial Primary Tumor Diagnosis19-Apr-2016Site of Primary TumorMediastinal NodesSite of MetastasisRegional Nodes, Bone Marrow, LiverWas Subject on previously on ChemotherapyYes since 25-May-2016 1 cycle R-EPOCH Current ChemotherapyRMA (Rituximab,HD-MTX, Ara-C)
DLS16-23889-SMethotrexateRussiaSerum1.006.00$150.0064 YFWhite<-70C22-Jul-16Abbott TDx FLx0.81 uU/mLMethotrexateClinical DiagnosisNHL, T-Cell LymphomaStagingStage IV; Grade G324-May-16$150.00Menopausal StatusPostSmoking HistoryFormer10-15 cigs/day for 15 yearsDate of Initial Primary Tumor Diagnosis19-Apr-2016Site of Primary TumorMediastinal NodesSite of MetastasisRegional Nodes, Bone Marrow, LiverWas Subject on previously on ChemotherapyYes since 25-May-2016 1 cycle R-EPOCH Current ChemotherapyRMA (Rituximab,HD-MTX, Ara-C)
DLS16-23891-LHMethotrexateRussiaL. Heparin Plasma1.001.00$150.0066 YFWhite<-70C07-Dec-16Abbott TDx FLx0.15 uU/mLMethotrexateClinical DiagnosisNHL, B-Cell Lymphoma (DBLCL)StagingStage III; Grade G315-Jul-16$150.00Menopausal StatusPostSmoking HistoryFormer5-10 cigs/day for 20 yearsDate of Initial Primary Tumor Diagnosis11-Jul-2016Site of Primary TumorRegional Nodes, MediastinalSite of MetastasisRetroperitoneal Nodes, Spleen Was Subject on previously on ChemotherapyYes since 18-Jul-2016 6 cycles R-CHOPCurrent ChemotherapyHD-MTX
DLS16-23891-SMethotrexateRussiaSerum1.006.00$150.0066 YFWhite<-70C07-Dec-16Abbott TDx FLx0.15 uU/mLMethotrexateClinical DiagnosisNHL, B-Cell Lymphoma (DBLCL)StagingStage III; Grade G315-Jul-16$150.00Menopausal StatusPostSmoking HistoryFormer5-10 cigs/day for 20 yearsDate of Initial Primary Tumor Diagnosis11-Jul-2016Site of Primary TumorRegional Nodes, MediastinalSite of MetastasisRetroperitoneal Nodes, Spleen Was Subject on previously on ChemotherapyYes since 18-Jul-2016 6 cycles R-CHOPCurrent ChemotherapyHD-MTX
DLS16-23900-LHMethotrexateRussiaL. Heparin Plasma1.001.00$150.0061 YMWhite<-70C29-Aug-16Abbott TDx FLx0.10 uU/mLMethotrexateClinical DiagnosisAcute Lymphoblastic Leukemia (pre-B)StagingStage IV14-May-16$150.00Menopausal StatusN/ASmoking HistoryNoneN/ADate of Initial Primary Tumor Diagnosis12-May-2016Site of Primary TumorBone MarrowSite of MetastasisLiver, Central Nervous SystemWas Subject on previously on ChemotherapyInduction block A (ALL 2009 and since 15-May-2016), Current ChemotherapyHD-MTX
DLS16-23900-SMethotrexateRussiaSerum1.0010.00$150.0061 YMWhite<-70C29-Aug-16Abbott TDx FLx0.10 uU/mLMethotrexateClinical DiagnosisAcute Lymphoblastic Leukemia (pre-B)StagingStage IV14-May-16$150.00Menopausal StatusN/ASmoking HistoryNoneN/ADate of Initial Primary Tumor Diagnosis12-May-2016Site of Primary TumorBone MarrowSite of MetastasisLiver, Central Nervous SystemWas Subject on previously on ChemotherapyInduction block A (ALL 2009 and since 15-May-2016), Current ChemotherapyHD-MTX
DLS16-23912-SMethotrexateRussiaSerum1.003.00$150.0060 YFAsian<-70C15-Sep-16Abbott TDx FLx0.08 uU/mLMethotrexateClinical DiagnosisNHL, T-Cell Lymphoma (relapse)StagingStage III; Grade G24-Apr-14$150.00Menopausal StatusPostSmoking HistoryNoneN/ADate of Initial Primary Tumor Diagnosis30-Mar-2014Site of Primary TumorRegional (Axillary) NodesSite of MetastasisMediastinum Was Subject on previously on ChemotherapyYes since 4-Apr-2014 6 cycles R-CHOP Current ChemotherapyHyper CVAD (HD-MTX)
DLS17-017583MethotrexateUSAL. Heparin Plasma1.001.00$75.0015 YFBlack<-70C15-Jun-17Roche cobas c5020.21 umol/LMethotrexate$75.00C40.22 C78.01 C78.02 C41.4 Z51.11 C79.51 M21.70 M84.362D M79.672 G89.18 G89.3
DLS17-017718MethotrexateUSAL. Heparin Plasma1.501.00$75.0067 YMWhite<-70C25-Jun-17Roche cobas c5020.1 umol/LMethotrexate$75.00C85.99 G57.00 G56.00 C85.80 M65.30 B02.29 M47.9 G62.9 G40.201 Z87.898 K59.01 E87.8 C83.30
DLS17-017719MethotrexateUSAL. Heparin Plasma1.251.00$75.0067 YMWhite<-70C23-Jun-17Roche cobas c5020.64 umol/LMethotrexate$75.00C85.99 G57.00 G56.00 C85.80 M65.30 B02.29 M47.9 G62.9 G40.201 Z87.898 K59.01 E87.8 C83.30
DLS17-022021MethotrexateUSAPlasma1.001.00$75.0052 YFU/A<-70C12-Aug-17Abbott FLX0.1 umol/LMethotrexate$75.00
DLS17-022023MethotrexateUSAPlasma1.501.00$75.0052 YFU/A<-70C11-Aug-17Abbott FLX0.12 umol/LMethotrexate$75.00
DLS17-022024MethotrexateUSAPlasma1.501.00$75.0052 YFU/A<-70C11-Aug-17Abbott FLX0.13 umol/LMethotrexate$75.00
DLS16-23859-SMethotrexateRussiaSerum1.008.00$150.0058 YFWhite<-70C26-May-17Abbott TDx FLx2.9 ug/mLMethotrexateClinical DiagnosisAcute Lymphoblastic Leukemia (ALL) T-cellStagingStage IV, Grade N/A23-Apr-17$150.00Menopausal StatusPostSmoking HistoryNoneDate of Initial Primary Tumor Diagnosis9-Apr-2017Site of Primary TumorBone MarrowSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23859-LHMethotrexateRussiaL. Heparin Plasma1.002.00$150.0058 YFWhite<-70C26-May-17Abbott TDx FLx2.9 ug/mLMethotrexateClinical DiagnosisAcute Lymphoblastic Leukemia (ALL) T-cellStagingStage IV, Grade N/A23-Apr-17$150.00Menopausal StatusPostSmoking HistoryNoneDate of Initial Primary Tumor Diagnosis9-Apr-2017Site of Primary TumorBone MarrowSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23861-SMethotrexateRussiaSerum1.003.00$150.0058 YFWhite<-70C22-May-17Abbott TDx FLx0.11 ug/mLMethotrexateClinical DiagnosisAcute Lymphoblastic Leukemia (ALL) Pre-BStagingStage IV, Grade N/A9-Mar-17$150.00Menopausal StatusN/ASmoking HistoryFormer 10-15 cigs/day 20 yearsDate of Initial Primary Tumor Diagnosis2-Mar-2017Site of Primary TumorBone MarrowSite of MetastasisLiver, SpleenHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23861-LHMethotrexateRussiaL. Heparin Plasma1.002.00$150.0058 YFWhite<-70C22-May-17Abbott TDx FLx0.11 ug/mLMethotrexateClinical DiagnosisAcute Lymphoblastic Leukemia (ALL) Pre-BStagingStage IV, Grade N/A9-Mar-17$150.00Menopausal StatusN/ASmoking HistoryFormer 10-15 cigs/day 20 yearsDate of Initial Primary Tumor Diagnosis2-Mar-2017Site of Primary TumorBone MarrowSite of MetastasisLiver, SpleenHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23864-SMethotrexateRussiaSerum1.003.00$150.0049 YFAsian<-70C19-Apr-17Abbott TDx FLx0.12 ug/mLMethotrexateClinical DiagnosisAcute Lymphoblastic Leukemia (ALL) B-cellStagingStage IV, Grade G424-Feb-17$150.00Menopausal StatusPreSmoking HistoryFormer 5-10 cigs/day 15 yearsDate of Initial Primary Tumor Diagnosis18-Feb-2017Site of Primary TumorBone MarrowSite of MetastasisCentral Nervous System History of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23864-LHMethotrexateRussiaL. Heparin Plasma1.001.00$150.0049 YFAsian<-70C19-Apr-17Abbott TDx FLx0.12 ug/mLMethotrexateClinical DiagnosisAcute Lymphoblastic Leukemia (ALL) B-cellStagingStage IV, Grade G424-Feb-17$150.00Menopausal StatusPreSmoking HistoryFormer 5-10 cigs/day 15 yearsDate of Initial Primary Tumor Diagnosis18-Feb-2017Site of Primary TumorBone MarrowSite of MetastasisCentral Nervous System History of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23869-SMethotrexateRussiaSerum1.004.00$150.0067 YFWhite<-70C29-Apr-17Abbott TDx FLx0.08 ug/mLMethotrexateClinical DiagnosisAnaplastic NHL (relapse)StagingStage IV, Grade G326-Apr-17$150.00Menopausal StatusPostSmoking HistoryNoneDate of Initial Primary Tumor Diagnosis4-Jan-2016Site of Primary TumorRegional (Axillary) NodesSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23870-SMethotrexateRussiaSerum1.005.00$150.0044 YMAsian<-70C14-Mar-17Abbott TDx FLx0.12 ug/mLMethotrexateClinical DiagnosisNHL, DLBCL, CD20+ StagingStage IV, Grade G41-Feb-17$150.00Menopausal StatusN/ASmoking HistoryFormer 15-20 cigs/day 20 yearsDate of Initial Primary Tumor Diagnosis12-Jan-2017Site of Primary TumorRegional Nodes (Mediastinal) Site of MetastasisSpleen, Bone Marrow, Central Nervous System History of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23872-SMethotrexateRussiaSerum1.003.00$150.0059 YFWhite<-70C12-Apr-17Abbott TDx FLx0.09 ug/mLMethotrexateClinical DiagnosisNHL, DLBCL, CD20+, RelapseStagingStage IV, Grade G34-Mar-17$150.00Menopausal StatusPostSmoking HistoryNoneDate of Initial Primary Tumor Diagnosis24-Oct-2015Site of Primary TumorMesenterial Nodes, StomachSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23873-SMethotrexateRussiaSerum1.007.00$150.0049 YMWhite<-70C13-May-17Abbott TDx FLx0.18 ug/mLMethotrexateClinical DiagnosisNHL, Follicular Lymphoma RelapseStagingStage IV, Grade G34-May-17$150.00Menopausal StatusN/ASmoking HistoryFormer 5-10 cigs/day 10 yearsDate of Initial Primary Tumor Diagnosis28-Jun-2016Site of Primary TumorRegional (Axillary) Nodes, SubclavicularSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23896-SMethotrexateRussiaSerum1.006.00$150.0057 YFWhite<-70C24-Feb-17Abbott TDx FLx0.28 ug/mLMethotrexateClinical DiagnosisNHL, B-Cell Mediastinal Lymphoma StagingStage IV, Grade G326-Jan-17$150.00Menopausal StatusPeriSmoking HistoryNoneDate of Initial Primary Tumor Diagnosis19-Jan-2017Site of Primary TumorMediastinal NodesSite of MetastasisBone MarrowHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23901-SMethotrexateRussiaSerum1.007.00$150.0050 YFWhite<-70C10-Apr-17Abbott TDx FLx8.56 ug/mLMethotrexateClinical DiagnosisNHL, DLBCL, CD20+, RelapseStagingStage IV, Grade G31-Mar-17$150.00Menopausal StatusPreSmoking HistoryNoneDate of Initial Primary Tumor Diagnosis4-Nov-2015Site of Primary TumorRegional (Axillary) NodesSite of MetastasisMediastinal Nodes, Involvement of Bone Marrow as a manifestation of relapseHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23901-LHMethotrexateRussiaL. Heparin Plasma1.001.00$150.0050 YFWhite<-70C10-Apr-17Abbott TDx FLx8.56 ug/mLMethotrexateClinical DiagnosisNHL, DLBCL, CD20+, RelapseStagingStage IV, Grade G31-Mar-17$150.00Menopausal StatusPreSmoking HistoryNoneDate of Initial Primary Tumor Diagnosis4-Nov-2015Site of Primary TumorRegional (Axillary) NodesSite of MetastasisMediastinal Nodes, Involvement of Bone Marrow as a manifestation of relapseHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23905-SMethotrexateRussiaSerum1.003.00$150.0054 YFAsian<-70C13-Apr-17Abbott TDx FLx0.17 ug/mLMethotrexateClinical DiagnosisNHL, Follicular Type progressionStagingStage IV, Grade G38-Feb-17$150.00Menopausal StatusPeriSmoking HistoryNoneDate of Initial Primary Tumor Diagnosis2-Mar-2016Site of Primary TumorRegional (Axillary) NodesSite of MetastasisCentral Nervous System (at the moment of progression)History of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23856-LHMethotrexateRussiaL. Heparin Plasma1.002.00$150.0054 YMAsian<-70C01-Apr-17Abbott TDx FLx0.12 ug/mLMethotrexateClinical DiagnosisNHL, DLBCL, CD20+, RelapseStagingStage IV, Grade G324-Dec-15$150.00Menopausal StatusN/ASmoking HistoryFormer 12-15 cigs/day 20 yearsDate of Initial Primary Tumor Diagnosis16-Dec-2015Site of Primary TumorStomach; Regional NodesSite of MetastasisLiver, Bone Marrow (on relapse)History of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23856-SMethotrexateRussiaSerum1.003.00$150.0054 YMAsian<-70C01-Apr-17Abbott TDx FLx0.12 ug/mLMethotrexateClinical DiagnosisNHL, DLBCL, CD20+, RelapseStagingStage IV, Grade G324-Dec-15$150.00Menopausal StatusN/ASmoking HistoryFormer 12-15 cigs/day 20 yearsDate of Initial Primary Tumor Diagnosis16-Dec-2015Site of Primary TumorStomach; Regional NodesSite of MetastasisLiver, Bone Marrow (on relapse)History of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23857-LHMethotrexateRussiaL. Heparin Plasma1.001.00$150.0061 YFWhite<-70C08-Jul-17Abbott TDx FLx0.36 ug/mLMethotrexateClinical DiagnosisNHL, DLBCL, CD20+, RelapseStagingStage IV, Grade G33-Jul-17$150.00Menopausal StatusPostSmoking HistoryNoneDate of Initial Primary Tumor Diagnosis9-Oct-2016Site of Primary TumorMediastinal LymphomaSite of MetastasisBone Marrow (on relapse); Primary N/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23857-SMethotrexateRussiaSerum1.007.00$150.0061 YFWhite<-70C08-Jul-17Abbott TDx FLx0.36 ug/mLMethotrexateClinical DiagnosisNHL, DLBCL, CD20+, RelapseStagingStage IV, Grade G33-Jul-17$150.00Menopausal StatusPostSmoking HistoryNoneDate of Initial Primary Tumor Diagnosis9-Oct-2016Site of Primary TumorMediastinal LymphomaSite of MetastasisBone Marrow (on relapse); Primary N/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23858-LHMethotrexateRussiaL. Heparin Plasma1.002.00$150.0058 YMWhite<-70C05-Jun-17Abbott TDx FLx0.12 ug/mLMethotrexateClinical DiagnosisBurkitt's lymphoma, CD20+StagingStage IV, Grade G32-Jun-17$150.00Menopausal StatusN/ASmoking HistoryFormer 10-15 cigs/day 25 yearsDate of Initial Primary Tumor Diagnosis29-May-2017Site of Primary TumorRegional Nodes (Mesenterial)Site of MetastasisSpleen; Liver; Bone MarrowHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23858-SMethotrexateRussiaSerum1.005.00$150.0058 YMWhite<-70C05-Jun-17Abbott TDx FLx0.12 ug/mLMethotrexateClinical DiagnosisBurkitt's lymphoma, CD20+StagingStage IV, Grade G32-Jun-17$150.00Menopausal StatusN/ASmoking HistoryFormer 10-15 cigs/day 25 yearsDate of Initial Primary Tumor Diagnosis29-May-2017Site of Primary TumorRegional Nodes (Mesenterial)Site of MetastasisSpleen; Liver; Bone MarrowHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23863-LHMethotrexateRussiaL. Heparin Plasma1.001.00$150.0048 YMWhite<-70C17-Jun-17Abbott TDx FLx1.85 ug/mLMethotrexateClinical DiagnosisAcute Lymphoblastic Leukemia (ALL), B-II variant, CD20+StagingStage IV, Grade N/A2-May-17$150.00Menopausal StatusN/ASmoking HistoryFormer 10-20 cigs/day 15-17 yearsDate of Initial Primary Tumor Diagnosis25-Apr-2017Site of Primary TumorBone MarrowSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23863-SMethotrexateRussiaSerum1.004.00$150.0048 YMWhite<-70C17-Jun-17Abbott TDx FLx1.85 ug/mLMethotrexateClinical DiagnosisAcute Lymphoblastic Leukemia (ALL), B-II variant, CD20+StagingStage IV, Grade N/A2-May-17$150.00Menopausal StatusN/ASmoking HistoryFormer 10-20 cigs/day 15-17 yearsDate of Initial Primary Tumor Diagnosis25-Apr-2017Site of Primary TumorBone MarrowSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23868-LHMethotrexateRussiaL. Heparin Plasma1.002.00$150.0061 YMWhite<-70C25-May-17Abbott TDx FLx0.84 ug/mLMethotrexateClinical DiagnosisNHL, DLBCL, CD20+ StagingStage IV, Grade G37-Feb-17$150.00Menopausal StatusN/ASmoking HistoryFormer 20-25 cigs/day 30 yearsDate of Initial Primary Tumor Diagnosis31-Jan-2017Site of Primary TumorGastric tumorSite of MetastasisRegional Nodes (Abdominals), Bone Marrow, LiverHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23868-SMethotrexateRussiaSerum1.001.00$150.0061 YMWhite<-70C25-May-17Abbott TDx FLx0.84 ug/mLMethotrexateClinical DiagnosisNHL, DLBCL, CD20+ StagingStage IV, Grade G37-Feb-17$150.00Menopausal StatusN/ASmoking HistoryFormer 20-25 cigs/day 30 yearsDate of Initial Primary Tumor Diagnosis31-Jan-2017Site of Primary TumorGastric tumorSite of MetastasisRegional Nodes (Abdominals), Bone Marrow, LiverHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23874-LHMethotrexateRussiaL. Heparin Plasma1.002.00$150.0036 YMWhite<-70C04-Jun-17Abbott TDx FLx0.08 ug/mLMethotrexateClinical DiagnosisNHL, DLBCL, CD20+ StagingStage IV, Grade G417-Feb-17$150.00Menopausal StatusN/ASmoking HistoryNoneDate of Initial Primary Tumor Diagnosis2-Feb-2017Site of Primary TumorRegional Nodes (Subclavicular)Site of MetastasisMediastinal Nodes, Bone MarrowHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23874-SMethotrexateRussiaSerum1.008.00$150.0036 YMWhite<-70C04-Jun-17Abbott TDx FLx0.08 ug/mLMethotrexateClinical DiagnosisNHL, DLBCL, CD20+ StagingStage IV, Grade G417-Feb-17$150.00Menopausal StatusN/ASmoking HistoryNoneDate of Initial Primary Tumor Diagnosis2-Feb-2017Site of Primary TumorRegional Nodes (Subclavicular)Site of MetastasisMediastinal Nodes, Bone MarrowHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23898-LHMethotrexateRussiaL. Heparin Plasma1.001.00$150.0058 YFWhite<-70C25-Jun-17Abbott TDx FLx0.62 ug/mLMethotrexateClinical DiagnosisAnaplastic NHL (relapse)StagingStage IV, Grade G320-Jun-17$150.00Menopausal StatusPostSmoking HistoryFormer 5-10 cigs/day 20 yearsDate of Initial Primary Tumor Diagnosis14-Apr-2016Site of Primary TumorRegional (Cervical, Axillary) NodesSite of MetastasisBone Marrow (on relapse); Primary N/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23898-SMethotrexateRussiaSerum1.006.00$150.0058 YFWhite<-70C25-Jun-17Abbott TDx FLx0.62 ug/mLMethotrexateClinical DiagnosisAnaplastic NHL (relapse)StagingStage IV, Grade G320-Jun-17$150.00Menopausal StatusPostSmoking HistoryFormer 5-10 cigs/day 20 yearsDate of Initial Primary Tumor Diagnosis14-Apr-2016Site of Primary TumorRegional (Cervical, Axillary) NodesSite of MetastasisBone Marrow (on relapse); Primary N/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23902-LHMethotrexateRussiaL. Heparin Plasma1.001.00$150.0050 YMWhite<-70C14-Jun-17Abbott TDx FLx0.11 ug/mLMethotrexateClinical DiagnosisNHL, DLBCL, CD20+ StagingStage IV, Grade G310-Mar-17$150.00Menopausal StatusN/ASmoking HistoryFormer 12-18 cigs/day 15-20 yearsDate of Initial Primary Tumor Diagnosis2-Mar-2017Site of Primary TumorCentral Nervous SystemSite of MetastasisNasopharynx, Liver, Bone MarrowHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23902-SMethotrexateRussiaSerum1.005.00$150.0050 YMWhite<-70C14-Jun-17Abbott TDx FLx0.11 ug/mLMethotrexateClinical DiagnosisNHL, DLBCL, CD20+ StagingStage IV, Grade G310-Mar-17$150.00Menopausal StatusN/ASmoking HistoryFormer 12-18 cigs/day 15-20 yearsDate of Initial Primary Tumor Diagnosis2-Mar-2017Site of Primary TumorCentral Nervous SystemSite of MetastasisNasopharynx, Liver, Bone MarrowHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS17-018332MethotrexateUSAL. Heparin Plasma1.501.00$75.0048 YMWhite<-70C03-Jul-17Roche cobas c5020.35 umol/LMethotrexate$75.00E03.9 R60.0 R11.2 I82.409 R53.1 K21.9 R52 D61.810 J90 C85.89 B34.8 T38.0X1A
DLS17-018958MethotrexateUSAL. Heparin Plasma1.001.00$75.0014 YFBlack<-70C23-Jul-17Roche cobas c5020.3 umol/LMethotrexate$75.00C40.22 C78.01 C78.02 C41.4 Z51.11 C79.51 M21.70 M84.362D M79.672 G89.3 C41.9
DLS17-018960MethotrexateUSAL. Heparin Plasma1.501.00$75.0068 YMWhite<-70C22-Jul-17Roche cobas c5020.12 umol/LMethotrexate$75.00I49.8 M48.06 M54.5 M72.9 R41.82 E78.5 Z51.11 Z86.79 M1A.9XX0 D72.829 K21.9 E87.8 Z79.899 I95.1 N17.9 B37.0 R61 K62.5 K64.8 R74.0 R50.9 R60.0
DLS17-018961MethotrexateUSAL. Heparin Plasma1.501.00$75.0067 YMWhite<-70C22-Jul-17Roche cobas c5020.15 umol/LMethotrexate$75.00C85.99 G57.00 G56.00 C85.80 M65.30 M47.9 G62.9 G40.201 Z87.898 R11.2 E87.8 C83.30
DLS17-018962MethotrexateUSAL. Heparin Plasma1.001.00$75.0067 YMWhite<-70C21-Jul-17Roche cobas c5020.21 umol/LMethotrexate$75.00C85.99 G57.00 G56.00 C85.80 M65.30 M47.9 G62.9 G40.201 Z87.898 R11.2 E87.8 C83.30
DLS17-019431MethotrexateUSAL. Heparin Plasma1.501.00$75.0062 YFWhite<-70C28-Jul-17Roche cobas c5020.06 umol/LMethotrexate$75.00D64.9 IMO0001 F19.20 M51.36 M51.37 M41.9 Z87.891 F99 M15.9 F34.1 J44.9 M54.9 G47.33 N20.0 F33.41
DLS17-020013MethotrexateUSAL. Heparin Plasma1.501.00$75.0068 YMWhite<-70C12-Aug-17Roche cobas c5020.11 umol/LMethotrexate$75.00I49.8 M48.06 M54.5 M72.9 R41.82 E78.5 Z51.11 Z86.79 M1A.9XX0 D72.829 K21.9 E87.8 Z79.899 I95.1 N17.9 B37.0 R61 K62.5 K64.8 R74.0 R50.9 R60.0
DLS17-020014MethotrexateUSAL. Heparin Plasma1.001.00$75.005 YFWhite<-70C12-Aug-17Roche cobas c5020.09 umol/LMethotrexate$75.00C91.00 Z51.11
DLS17-020015MethotrexateUSAL. Heparin Plasma1.501.00$75.0068 YMWhite<-70C11-Aug-17Roche cobas c5020.13 umol/LMethotrexate$75.00I49.8 M48.06 M54.5 M72.9 R41.82 E78.5 Z51.11 Z86.79 M1A.9XX0 D72.829 K21.9 E87.8 Z79.899 I95.1 N17.9 B37.0 R61 K62.5 K64.8 R74.0 R50.9 R60.0
DLS17-020016MethotrexateUSAL. Heparin Plasma1.501.00$75.005 YFWhite<-70C11-Aug-17Roche cobas c5020.38 umol/LMethotrexate$75.00C91.00 Z51.11
DLS17-020018MethotrexateUSAL. Heparin Plasma1.501.00$75.0068 YMWhite<-70C10-Aug-17Roche cobas c5020.17 umol/LMethotrexate$75.00I49.8 M48.06 M54.5 M72.9 R41.82 E78.5 Z51.11 Z86.79 M1A.9XX0 D72.829 K21.9 E87.8 Z79.899 I95.1 N17.9 B37.0 R61 K62.5 K64.8 R74.0 R50.9 R60.0
DLS17-020102MethotrexateUSAL. Heparin Plasma1.001.00$75.0031 YMWhite<-70C18-Aug-17Roche cobas c5020.11 umol/LMethotrexate$75.00D70.9 C91.00
DLS17-020103MethotrexateUSAL. Heparin Plasma1.501.00$75.0065 YFWhite<-70C17-Aug-17Roche cobas c5020.12 umol/LMethotrexate$75.00R56.9 J44.9 D84.9 K12.31 R60.0 D69.59 I82.403 G89.3 I87.2 M62.81 C83.30
DLS17-020177MethotrexateUSAL. Heparin Plasma1.501.00$75.0067 YMWhite<-70C27-Aug-17Roche cobas c5020.1 umol/LMethotrexate$75.00C85.99 G57.00 G56.00 C85.80 M65.30 M47.9 G62.9 G40.201 Z87.898 R11.2 E87.8 C83.30
DLS17-020178MethotrexateUSAL. Heparin Plasma1.501.00$75.0067 YMWhite<-70C26-Aug-17Roche cobas c5020.19 umol/LMethotrexate$75.00C85.99 G57.00 G56.00 C85.80 M65.30 M47.9 G62.9 G40.201 Z87.898 R11.2 E87.8 C83.30
DLS17-020179MethotrexateUSAL. Heparin Plasma1.501.00$75.0064 YFWhite<-70C25-Aug-17Roche cobas c5020.1 umol/LMethotrexate$75.00J30.9 J45.909 R32 E78.5 D36.7 I05.9 Z51.11 D70.1 Z91.89 N39.0 E87.8 E44.0 K30 Z79.899
DLS17-020180MethotrexateUSAL. Heparin Plasma1.001.00$75.005 YFWhite<-70C24-Aug-17Roche cobas c5020.27 umol/LMethotrexate$75.00C91.00 Z51.11
DLS17-018331MethotrexateUSAL. Heparin Plasma1.251.00$75.0059 YMWhite<-70C05-Jul-17Roche cobas c5021.07 umol/LMethotrexate$75.00Z91.89 C85.10 R11.2 C85.89 E87.8 Z91.09 R51 K21.9 E78.5 R26.89 C85.90 D86.9 G93.6
DLS17-018959MethotrexateUSAL. Heparin Plasma1.251.00$75.0014 YFBlack<-70C22-Jul-17Roche cobas c5029.6 umol/LMethotrexate$75.00C40.22 C78.01 C78.02 C41.4 Z51.11 C79.51 M21.70 M84.362D M79.672 G89.3 C41.9
DLS17-018963MethotrexateUSAL. Heparin Plasma1.251.00$75.0067 YMWhite<-70C20-Jul-17Roche cobas c5020.5 umol/LMethotrexate$75.00C85.99 G57.00 G56.00 C85.80 M65.30 M47.9 G62.9 G40.201 Z87.898 R11.2 E87.8 C83.30
DLS17-018964MethotrexateUSAL. Heparin Plasma1.501.00$75.0068 YMWhite<-70C20-Jul-17Roche cobas c5020.64 umol/LMethotrexate$75.00I49.8 M48.06 M54.5 M72.9 R41.82 E78.5 Z51.11 Z86.79 M1A.9XX0 D72.829 K21.9 E87.8 Z79.899 I95.1 N17.9 B37.0 R61 K62.5 K64.8 R74.0 R50.9 R60.0
DLS17-018965MethotrexateUSAL. Heparin Plasma1.251.00$75.0067 YMWhite<-70C19-Jul-17Roche cobas c50219 umol/LMethotrexate$75.00C85.99 G57.00 G56.00 C85.80 M65.30 M47.9 G62.9 G40.201 Z87.898 R11.2 E87.8 C83.30
DLS17-020017MethotrexateUSAL. Heparin Plasma1.251.00$75.005 YFWhite<-70C10-Aug-17Roche cobas c5021.03 umol/LMethotrexate$75.00C91.00 Z51.11
DLS17-020019MethotrexateUSAL. Heparin Plasma1.251.00$75.005 YFWhite<-70C10-Aug-17Roche cobas c50266 umol/LMethotrexate$75.00C91.00 Z51.11
DLS17-020181MethotrexateUSAL. Heparin Plasma1.501.00$75.005 YFWhite<-70C23-Aug-17Roche cobas c50271 umol/LMethotrexate$75.00C91.00 Z51.11
DLS17-020240MethotrexateUSAL. Heparin Plasma1.001.00$75.0020 YMWhite<-70C29-Aug-17Roche cobas c5020.92 umol/LMethotrexate$75.00C83.50
DLS17-020241MethotrexateUSAL. Heparin Plasma1.501.00$75.0073 YFWhite<-70C29-Aug-17Roche cobas c50211.7 umol/LMethotrexate$75.00R53.1 R00.2 R53.83 M60.9 E43 C85.10
DLS17-038459MethotrexateUSAL. Heparin Plasma1.001.00$75.0020 YMWhite<-70C01-Nov-17Roche cobas c5020.11 umol/LMethotrexate$75.00E80.4 C85.89
DLS17-020585MethotrexateUSAL. Heparin Plasma1.251.00$75.0076 YMWhite<-70C03-Oct-17Roche cobas c5020.12 umol/LMethotrexate$75.00C85.89
DLS17-038457MethotrexateUSAL. Heparin Plasma1.501.00$75.0035 YMWhite<-70C05-Nov-17Roche cobas c5020.18 umol/LMethotrexate$75.00D49.6 H54.7 J98.59 H53.47 R44.1 Z51.11 E03.9 R52 R74.0 T45.1X1A
DLS17-038458MethotrexateUSAL. Heparin Plasma1.501.00$75.0035 YMWhite<-70C04-Nov-17Roche cobas c5020.19 umol/LMethotrexate$75.00D49.6 H54.7 J98.59 H53.47 R44.1 Z51.11 E03.9 R52 R74.0 T45.1X1A
DLS17-020586MethotrexateUSAL. Heparin Plasma1.501.00$75.0076 YMWhite<-70C01-Oct-17Roche cobas c5020.23 umol/LMethotrexate$75.00C85.89
DLS17-020587MethotrexateUSAL. Heparin Plasma1.501.00$75.0076 YMWhite<-70C30-Sep-17Roche cobas c5020.64 umol/LMethotrexate$75.00C85.89
DLS17-038460MethotrexateUSAL. Heparin Plasma1.001.00$75.0020 YMWhite<-70C31-Oct-17Roche cobas c5020.75 umol/LMethotrexate$75.00E80.4 C85.89
DLS17-020588MethotrexateUSAL. Heparin Plasma1.501.00$75.0076 YMWhite<-70C29-Sep-17Roche cobas c5022.00 umol/LMethotrexate$75.00C85.89
DLS17-040688MethotrexateUSAL. Heparin Plasma1.501.00$75.0075 YFWhite<-70C25-Feb-18Roche cobas c 502 Analyzer0.08 umol/LMethotrexate$75.00R92.0 C85.89
KH18-12363MethotrexateUSAL. Heparin Plasma1.001.00$75.0012 YMWhite<-70C28-Feb-18Abbott TDx FLx8.10 umol/LMethotrexate$75.00
KH18-12364MethotrexateUSAL. Heparin Plasma1.001.00$75.0012 YMWhite<-70C28-Feb-18Abbott TDx FLx1.09 umol/LMethotrexate$75.00
KH18-13238MethotrexateUSAL. Heparin Plasma1.001.00$75.0010 YMBlack<-70C13-Mar-18Abbott TDx FLx9.67 umol/LMethotrexate$75.00
KH18-13239MethotrexateUSAL. Heparin Plasma1.501.00$75.0010 YMBlack<-70C13-Mar-18Abbott TDx FLx1166 umol/LMethotrexate$75.00
KH18-13240MethotrexateUSAL. Heparin Plasma1.251.00$75.0012 YMWhite<-70C05-Mar-18Abbott TDx FLx0.09 umol/LMethotrexate$75.00
DLS17-041281MethotrexateUSAL. Heparin Plasma1.001.00$75.0016 YFWhite<-70C24-Mar-18Roche cobas c 5020.05 umol/LMethotrexate$75.00D61.818 Z51.11 D64.9 D70.9 C91.00
KH18-13637MethotrexateUSAL. Heparin Plasma1.501.00$75.0010 YMBlack<-70C19-Mar-18Abbott TDx FLx1,140 umol/LMethotrexate$75.00
KH18-13638MethotrexateUSAL. Heparin Plasma1.251.00$75.0010 YMBlack<-70C20-Mar-18Abbott TDx FLx6.9 umol/LMethotrexate$75.00
KH18-13639MethotrexateUSAL. Heparin Plasma1.251.00$75.0010 YMBlack<-70C14-Mar-18Abbott TDx FLx0.32 umol/LMethotrexate$75.00
KH18-15215MethotrexateUSAL. Heparin Plasma1.501.00$75.0012 YMWhite<-70C26-Mar-18Abbott TDx FLx0.08 umol/LMethotrexate$75.00
KH18-15216MethotrexateUSAL. Heparin Plasma1.251.00$75.0012 YMWhite<-70C24-Mar-18Abbott TDx FLx0.19 umol/LMethotrexate$75.00
KH18-15217MethotrexateUSAL. Heparin Plasma1.001.00$75.0012 YMWhite<-70C25-Mar-18Abbott TDx FLx0.08 umol/LMethotrexate$75.00
KH18-15218MethotrexateUSAL. Heparin Plasma1.251.00$75.0012 YMWhite<-70C23-Mar-18Abbott TDx FLx0.25 umol/LMethotrexate$75.00
KH18-15219MethotrexateUSAL. Heparin Plasma1.501.00$75.0010 YMBlack<-70C22-Mar-18Abbott TDx FLx0.10 umol/LMethotrexate$75.00
DLS17-041372MethotrexateUSAL. Heparin Plasma1.501.00$75.0063 YMWhite<-70C28-Mar-18Roche cobas c5020.23 umol/LMethotrexate$75.00K74.60 K80.20 A41.9 K81.0
DLS17-041373MethotrexateUSAL. Heparin Plasma1.501.00$75.0074 YMWhite<-70C28-Mar-18Roche cobas c5022.7 umol/LMethotrexate$75.00H93.19 J34.89 C85.90
DLS17-041398MethotrexateUSAL. Heparin Plasma1.251.00$75.0063 YMWhite<-70C29-Mar-18Roche cobas c5020.05 umol/LMethotrexate$75.00K74.60 K80.20 A41.9 K81.0
DLS17-041430MethotrexateUSAL. Heparin Plasma1.001.00$75.0070 YMWhite<-70C05-Apr-18Roche cobas c5020.24 umol/LMethotrexate$75.00E78.5 K21.9 R42 H49.02 H53.2 H35.3131 H25.13 D49.6 N39.45 R26.9 R11.2 N39.3
DLS17-041463MethotrexateUSAL. Heparin Plasma1.501.00$75.0070 YMWhite<-70C06-Apr-18Roche cobas c5020.09 umol/LMethotrexate$75.00E78.5 K21.9 R42 H49.02 H53.2 H35.3131 H25.13 D49.6 N39.45 R26.9 R11.2 N39.3
DLS17-041464MethotrexateUSAL. Heparin Plasma1.501.00$75.0065 YMWhite<-70C06-Apr-18Roche cobas c5025.7 umol/LMethotrexate$75.00R78.81 E04.9 Z51.11 E44.0 B37.81 R33.9 K20.9
DLS17-041481MethotrexateUSAK2 EDTA Plasma1.001.00$75.0065 YMWhite<-70C06-Apr-18Roche cobas c5025.7 umol/LMethotrexate$75.00R78.81 E04.9 Z51.11 E44.0 B37.81 R33.9 K20.9
DLS17-041491MethotrexateUSAL. Heparin Plasma1.501.00$75.0065 YMWhite<-70C07-Apr-18Roche cobas c5020.47 umol/LMethotrexate$75.00R78.81 E04.9 Z51.11 E44.0 B37.81 R33.9 K20.9
DLS17-041500MethotrexateUSAL. Heparin Plasma1.501.00$75.0065 YMWhite<-70C08-Apr-18Roche cobas c5020.21 umol/LMethotrexate$75.00R78.81 E04.9 Z51.11 E44.0 B37.81 R33.9 K20.9
DLS17-041522MethotrexateUSAL. Heparin Plasma1.501.00$75.0065 YMWhite<-70C09-Apr-18Roche cobas c5020.12 umol/LMethotrexate$75.00R78.81 E04.9 Z51.11 E44.0 B37.81 R33.9 K20.9
DLS17-041606MethotrexateUSAL. Heparin Plasma1.501.00$75.0065 YMWhite<-70C10-Apr-18Roche cobas c5020.08 umol/LMethotrexate$75.00R78.81 E04.9 Z51.11 E44.0 B37.81 R33.9 K20.9
DLS17-041714MethotrexateUSAL. Heparin Plasma1.251.00$75.0016 YFWhite<-70C14-Apr-18Roche cobas c5020.24 umol/LMethotrexate$75.00D61.818 Z51.11 D64.9 D70.9 C91.00
DLS17-042079MethotrexateUSAL. Heparin Plasma1.501.00$75.0055 YMWhite<-70C27-Apr-18Roche cobas c5020.12 umol/LMethotrexate$75.00H52.4 R11.2 K21.9 F32.9 Z91.09 E87.8
DLS17-042338MethotrexateUSAL. Heparin Plasma1.501.00$75.0023 YMWhite<-70C03-May-18Roche cobas c5020.18 umol/LMethotrexate$75.00K08.89 J98.59 C91.01
DLS17-042339MethotrexateUSAL. Heparin Plasma1.251.00$75.0070 YMWhite<-70C03-May-18Roche cobas c5020.28 umol/LMethotrexate$75.00E78.5 K21.9 R42 H49.02 H53.2 H35.3131 H25.13 D49.6 N39.45 R26.9 R11.2 N39.3
DLS17-042340MethotrexateUSAL. Heparin Plasma1.001.00$75.0015 YMWhite<-70C01-May-18Roche cobas c50249 umol/LMethotrexate$75.00C91.01
DLS17-042341MethotrexateUSAL. Heparin Plasma1.501.00$75.0070 YMWhite<-70C02-May-18Roche cobas c5023.9 umol/LMethotrexate$75.00E78.5 K21.9 R42 H49.02 H53.2 H35.3131 H25.13 D49.6 N39.45 R26.9 R11.2 N39.3
DLS17-042406MethotrexateUSAL. Heparin Plasma1.001.00$75.0057 YMWhite<-70C04-May-18Roche cobas c5021.1 umol/LMethotrexate$75.00K75.81 E11.69 M16.9 M54.17 M48.062 F30.10 G47.09 F41.8 F69 D50.9 N17.9 E87.6 E44.0 R50.9 R41.0 R32 R15.9 F05 G93.9 E66.9 C85.89
DLS17-042407MethotrexateUSAL. Heparin Plasma1.501.00$75.0023 YMWhite<-70C04-May-18Roche cobas c5020.05 umol/LMethotrexate$75.00K08.89 J98.59 C91.01
DLS17-042434MethotrexateUSAL. Heparin Plasma1.001.00$75.0057 YMWhite<-70C05-May-18Roche cobas c5020.4 umol/LMethotrexate$75.00K75.81 E11.69 M16.9 M54.17 M48.062 F30.10 G47.09 F41.8 F69 D50.9 N17.9 E87.6 E44.0 R50.9 R41.0 R32 R15.9 F05 G93.9 E66.9 C85.89
DLS17-042435MethotrexateUSAL. Heparin Plasma1.501.00$75.0054 YFWhite<-70C05-May-18Roche cobas c5021.7 umol/LMethotrexate$75.00C85.99
DLS17-042449MethotrexateUSAL. Heparin Plasma1.001.00$75.0057 YMWhite<-70C06-May-18Roche cobas c5020.22 umol/LMethotrexate$75.00K75.81 E11.69 M16.9 M54.17 M48.062 F30.10 G47.09 F41.8 F69 D50.9 N17.9 E87.6 E44.0 R50.9 R41.0 R32 R15.9 F05 G93.9 E66.9 C85.89
DLS17-042543MethotrexateUSAL. Heparin Plasma1.001.00$75.0054 YMBlack<-70C07-May-18Roche cobas c5020.05 umol/LMethotrexate$75.00C91.Z0
DLS17-042544MethotrexateUSAL. Heparin Plasma1.001.00$75.0057 YMWhite<-70C07-May-18Roche cobas c5020.2 umol/LMethotrexate$75.00K75.81 E11.69 M16.9 M54.17 M48.062 F30.10 G47.09 F41.8 F69 D50.9 N17.9 E87.6 E44.0 R50.9 R41.0 R32 R15.9 F05 G93.9 E66.9 C85.89
DLS17-042545MethotrexateUSAL. Heparin Plasma1.001.00$75.0054 YFWhite<-70C07-May-18Roche cobas c5020.08 umol/LMethotrexate$75.00C85.99
DLS17-042685MethotrexateUSAL. Heparin Plasma1.001.00$75.0057 YMWhite<-70C08-May-18Roche cobas c5020.1 umol/LMethotrexate$75.00K75.81 E11.69 M16.9 M54.17 M48.062 F30.10 G47.09 F41.8 F69 D50.9 N17.9 E87.6 E44.0 R50.9 R41.0 R32 R15.9 F05 G93.9 E66.9 C85.89
DLS17-042686MethotrexateUSAL. Heparin Plasma1.001.00$75.0057 YMWhite<-70C09-May-18Roche cobas c5020.06 umol/LMethotrexate$75.00K75.81 E11.69 M16.9 M54.17 M48.062 F30.10 G47.09 F41.8 F69 D50.9 N17.9 E87.6 E44.0 R50.9 R41.0 R32 R15.9 F05 G93.9 E66.9 C85.89
DLS17-042815MethotrexateUSAL. Heparin Plasma1.501.00$75.0091 YMBlack<-70C14-May-18Roche cobas c5020.13 umol/LMethotrexate$75.00C83.39
DLS17-042904MethotrexateUSAL. Heparin Plasma1.001.00$75.0057 YMWhite<-70C17-May-18Roche cobas c5029.2 umol/LMethotrexate$75.00K75.81 E11.69 M16.9 M54.17 M48.062 F30.10 G47.09 F41.8 F69 D50.9 N17.9 E87.6 E44.0 R50.9 R41.0 R32 R15.9 F05 G93.9 E66.9 C85.89
DLS17-042905MethotrexateUSAL. Heparin Plasma1.251.00$75.0059 YMWhite<-70C17-May-18Roche cobas c5020.18 umol/LMethotrexate$75.00C85.89
DLS17-042906MethotrexateUSAL. Heparin Plasma1.501.00$75.0070 YMWhite<-70C17-May-18Roche cobas c5020.38 umol/LMethotrexate$75.00E78.5 K21.9 R42 H49.02 H53.2 H35.3131 H25.13 D49.6 N39.45 R26.9 R11.2 N39.3
DLS17-042907MethotrexateUSAL. Heparin Plasma1.251.00$75.0015 YMWhite<-70C17-May-18Roche cobas c5020.12 umol/LMethotrexate$75.00C91.01
DLS17-042908MethotrexateUSAL. Heparin Plasma1.501.00$75.0015 YMWhite<-70C15-May-18Roche cobas c50273 umol/LMethotrexate$75.00C91.01
DLS17-042909MethotrexateUSAL. Heparin Plasma1.501.00$75.0059 YMWhite<-70C16-May-18Roche cobas c5021.8 umol/LMethotrexate$75.00C85.89
DLS17-042987MethotrexateUSAL. Heparin Plasma1.001.00$75.0057 YMWhite<-70C18-May-18Roche cobas c5020.54 umol/LMethotrexate$75.00K75.81 E11.69 M16.9 M54.17 M48.062 F30.10 G47.09 F41.8 F69 D50.9 N17.9 E87.6 E44.0 R50.9 R41.0 R32 R15.9 F05 G93.9 E66.9 C85.89
DLS17-042988MethotrexateUSAL. Heparin Plasma1.501.00$75.0070 YMWhite<-70C18-May-18Roche cobas c5020.16 umol/LMethotrexate$75.00E78.5 K21.9 R42 H49.02 H53.2 H35.3131 H25.13 D49.6 N39.45 R26.9 R11.2 N39.3
DLS17-043074MethotrexateUSAL. Heparin Plasma1.501.00$75.0054 YFWhite<-70C19-May-18Roche cobas c5020.1 umol/LMethotrexate$75.00C85.99
DLS17-043052MethotrexateUSAL. Heparin Plasma1.251.00$75.0021 YMBlack<-70C20-May-18Roche cobas c5020.23 umol/LMethotrexate$75.00C91.00
DLS17-043069MethotrexateUSAL. Heparin Plasma1.001.00$75.0057 YMWhite<-70C21-May-18Roche cobas c5020.1 umol/LMethotrexate$75.00K75.81 E11.69 M16.9 M54.17 M48.062 F30.10 G47.09 F41.8 F69 D50.9 N17.9 E87.6 E44.0 R50.9 R41.0 R32 R15.9 F05 G93.9 E66.9 C85.89
DLS17-043070MethotrexateUSAL. Heparin Plasma1.501.00$75.0021 YMBlack<-70C21-May-18Roche cobas c5020.07 umol/LMethotrexate$75.00C91.00
DLS17-043822MethotrexateUSAL. Heparin Plasma1.501.00$75.0047 YFWhite<-70C28-May-18Roche cobas c5020.09 umol/LMethotrexate$75.00C83.38
DLS17-043823MethotrexateUSAL. Heparin Plasma1.001.00$75.0072 YFAsian<-70C28-May-18Roche cobas c5021.02 umol/LMethotrexate$75.00R91.8 M85.80 C83.30
DLS17-043855MethotrexateUSAL. Heparin Plasma1.501.00$75.0070 YMWhite<-70C31-May-18Roche cobas c5025.3 umol/LMethotrexate$75.00N52.9 C61
KH18-27169MethotrexateUSASerum1.001.00$75.0013 YFWhite<-70C12-Jun-18Abbott TDx FLx1,770 umol/LMethotrexate$75.00
KH18-27168MethotrexateUSASerum1.001.00$75.0013 YFWhite<-70C15-Jun-18Abbott TDx FLx0.07 umol/LMethotrexate$75.00

Keep in mind that all the samples comprised in the Research Sample Biobank represent only a small number of the clinical research specimens available through our Discovery Partners™ clinical research programs. If you can’t find the specific sample type, specimen or biofluids you are looking for please make sure to call our client services group at 805.528.4341 - and ask how we can help support your project from resources available at active clinical sites.

Please read carefully before purchasing:

Clinical specimens for research use only.

Transmissible Infectious Risk! May be HIV, HBV and HCV REACTIVE or of unknown infectious agent test status. Materials provided are derived from human blood, tissue and other bio-fluids. Handle all samples as if capable of transmitting infectious agents. Practice good laboratory technique and dispose of in properly marked medical waste.

If you need help searching for a LARGER SAMPLE SET with specific data elements, please contact our Client Services group who can format Excel spreadsheets for a comprehensive review of all available samples: USA (805) 528-4341

These products are supplied without warranty for suitability for specific applications or analytical determinations.